...
首页> 外文期刊>Cornea >Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.
【24h】

Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.

机译:联合使用浅表角膜切除术和结膜下贝伐单抗注射液治疗角膜新生血管。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To report the effect of superficial keratectomy combined with subconjunctival bevacizumab injection in 2 cases of corneal neovascularization (NV). METHODS: An interventional case series was undertaken on 2 patients with corneal NV: 1 due to sclerokeratitis secondary to rheumatoid arthritis and the other due to Terrien marginal degeneration. Both patients underwent superficial keratectomy combined with subconjunctival bevacizumab injection (2.5 mg/0.1 mL). RESULTS: Corneal NV regressed with the surgical removal and showed no signs of recurrence after 3 months of follow-up. Both patients reported dramatic subjective improvement in their vision within 1-2 weeks. Best corrected visual acuity improved in 1 patient. CONCLUSION: The combination of superficial keratectomy with subconjunctival injection of bevacizumab may offer a new strategy for the treatment of superficial corneal NV.
机译:目的:报道浅表角膜切除术联合结膜下贝伐单抗注射液治疗2例角膜新生血管(NV)的效果。方法:对2例角膜NV患者进行了干预,包括1例因类风湿性关节炎继发的巩膜炎,另一例因Terrien边缘变性。两名患者均接受了浅角膜切除联合结膜下贝伐单抗注射(2.5 mg / 0.1 mL)。结果:角膜NV因手术切除而退缩,并且在随访3个月后未见复发迹象。两名患者均报告称,​​他们在1-2周内主观视力有了明显改善。 1名患者的最佳矫正视力得到改善。结论:浅表角膜切除术联合结膜下注射贝伐单抗可能为治疗浅表角膜NV提供新的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号